Last updated: November 11, 2026
Peginesatide acetate, marketed as Omontys, was a synthetic erythropoiesis-stimulating agent developed by Affymax and commercialized in the U.S. by Takeda Pharmaceuticals. The FDA approved it in March 2012 for anemia associated with chronic kidney disease in adult patients on dialysis and in patients not on dialysis. Commercial availability ended less than a year later after reports of severe hypersensitivity reactions, including fatalities. The withdrawal eliminated future product revenue and ended Affymax’s commercial strategy. [1][2]
The product’s market proposition was a long-acting ESA administered once monthly, compared with more frequent dosing for epoetin products. That advantage was insufficient to overcome safety risk, limited market penetration, established competitors, reimbursement pressure, and the February 2013 recall.
What was peginesatide acetate and how did it work?
Peginesatide was a PEGylated peptide erythropoietin-receptor agonist. It was designed to stimulate erythropoiesis without using the amino-acid sequence of endogenous erythropoietin.
The product was supplied as peginesatide acetate injection under the brand name Omontys. Its primary clinical target was anemia associated with chronic kidney disease, a market dominated by erythropoietin products used in dialysis centers and nephrology practices.
The FDA-approved label covered:
| Attribute |
Omontys profile |
| Active ingredient |
Peginesatide acetate |
| Brand |
Omontys |
| Developer |
Affymax |
| U.S. commercial partner |
Takeda Pharmaceuticals |
| FDA approval |
March 27, 2012 |
| Indication |
Anemia due to chronic kidney disease |
| Dosing concept |
Once monthly |
| Route |
Intravenous or subcutaneous injection |
| Commercial status |
Withdrawn from U.S. distribution in 2013 |
| Primary withdrawal issue |
Serious hypersensitivity reactions, including anaphylaxis |
The FDA label warned about increased risks associated with ESA therapy, including death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and tumor progression or recurrence in certain cancer settings. Those class-wide warnings already created a demanding regulatory and commercial environment for new ESA products. [1]
How large was the peginesatide market opportunity?
Peginesatide entered a large but mature ESA market. The main commercial opportunity was the U.S. dialysis market, where treatment frequency, administration burden, facility economics, and reimbursement influenced product selection.
Before Omontys, the key competitors included:
| Product |
Company |
Typical commercial position |
| Epogen |
Amgen |
Established dialysis ESA, generally frequent dosing |
| Procrit |
Johnson & Johnson |
Major epoetin product across CKD and other anemia uses |
| Aranesp |
Amgen |
Longer-acting darbepoetin alfa |
| Mircera |
Roche |
Long-acting continuous erythropoietin receptor activator |
| Omontys |
Affymax/Takeda |
Once-monthly synthetic peptide ESA |
Omontys attempted to differentiate through monthly administration. That feature had potential value for dialysis providers because it could reduce injection frequency and simplify treatment schedules. The product entered against entrenched formularies, established clinical protocols, and competitors with extensive physician experience.
The market also faced structural pressure. ESA utilization declined after safety studies and regulatory warnings led clinicians to use lower hemoglobin targets. Medicare reimbursement changes reduced incentives for dialysis providers to maximize ESA utilization. These factors reduced the size and growth rate of the addressable market before Omontys had time to establish a stable commercial position.
What were Omontys sales and Affymax’s financial trajectory?
Affymax reported approximately $6.8 million in Omontys net product sales in 2012, its first commercial year. The figure was small relative to the addressable ESA market and reflected a short launch period, slow adoption, and commercial competition. [3]
The February 2013 withdrawal interrupted the launch before the product could reach meaningful scale. Affymax’s expected future royalty and product-related revenue stream effectively disappeared. The company subsequently reduced operations, terminated employees, and pursued a wind-down that culminated in bankruptcy proceedings.
Financial trajectory
| Period |
Commercial and financial event |
| 2006 |
Affymax and Takeda entered a collaboration covering development and commercialization |
| 2011 |
FDA review and launch preparation accelerated |
| March 2012 |
FDA approved Omontys |
| 2012 |
First commercial sales; Affymax reported about $6.8 million in net product sales |
| February 2013 |
Takeda and Affymax announced a voluntary nationwide recall |
| 2013 |
Product revenue ceased; Affymax sharply reduced operations |
| 2013-2014 |
Affymax pursued liquidation and bankruptcy-related wind-down activities |
Takeda’s consolidated reporting did not establish Omontys as a material standalone revenue contributor. The product’s short market life limited its impact on Takeda’s overall financial performance. For Affymax, the impact was much more severe because Omontys was the company’s principal commercial asset and the core economic basis for its relationship with Takeda.
The commercial failure also impaired the value of related intellectual property, development infrastructure, sales capabilities, and future milestone expectations. The product had generated a launch platform but no durable revenue base.
Why was Omontys withdrawn from the market?
The FDA and the companies identified serious hypersensitivity reactions, including anaphylaxis, as the reason for withdrawal.
In February 2013, Affymax and Takeda reported that serious hypersensitivity reactions had occurred in patients receiving Omontys. The companies recommended that healthcare professionals stop using the product and return unused inventory. The FDA reported 25 cases of serious hypersensitivity reactions, including seven deaths, among approximately 12,000 patients exposed to the product in the first year after approval. [2]
The issue was commercially decisive for three reasons:
- The events occurred soon after a new product launch, before prescribing habits were established.
- Anaphylaxis created an acute safety concern that was difficult to manage through routine labeling changes.
- Physicians and dialysis providers had established alternatives with longer safety and utilization histories.
The withdrawal destroyed the product’s ability to compete on convenience. Monthly administration had commercial value only if providers were willing to accept the product’s safety profile.
What was the FDA regulatory status of peginesatide?
Omontys received regular FDA approval rather than accelerated approval. The approval applied to anemia associated with chronic kidney disease in adult patients on dialysis and adults not on dialysis.
The product was later withdrawn from commercial distribution at the request of the manufacturer. The FDA’s drug-safety communications documented the recall and the clinical concern. [2]
The withdrawal did not create a viable regulatory pathway for relaunch. A relaunch would have required resolution of the hypersensitivity mechanism, manufacturing or formulation assessment, additional clinical evidence, and a risk-management strategy capable of restoring physician confidence. No commercial relaunch occurred.
FDA milestones
| Date |
Regulatory milestone |
| March 27, 2012 |
FDA approved Omontys |
| February 2013 |
FDA and manufacturers communicated serious hypersensitivity risk |
| February 2013 |
Nationwide voluntary recall and market withdrawal |
| After 2013 |
No sustained U.S. commercial relaunch |
What patents protected peginesatide acetate?
Peginesatide was protected by patents covering synthetic erythropoietin-receptor agonist peptides, PEG conjugates, compositions, pharmaceutical formulations, and methods of treating anemia. Affymax was the principal originating innovator, with Takeda holding commercial rights in the United States under the collaboration agreement.
The commercial patent position was less important than the safety event. Even a strong patent estate could not preserve revenue after a product withdrawal.
Public company filings described intellectual-property protection around the peginesatide program, including composition-of-matter and related patent rights. The expected commercial life of the product depended on both patent duration and regulatory exclusivity, but the 2013 withdrawal occurred before the market could test the durability of that protection. [3][4]
Formulation and manufacturing protection
The product’s technical barriers included:
- Synthesis of the peptide erythropoietin-receptor agonist.
- Site-specific or controlled PEG conjugation.
- Purification of the active conjugate.
- Control of aggregate levels and impurities.
- Sterile injectable formulation.
- Manufacturing consistency at commercial scale.
These barriers could have constrained follow-on competition. They did not prevent the safety-related commercial collapse.
Orange Book status
Omontys was an FDA-approved prescription product, but its listing became commercially inactive after withdrawal. The Orange Book status must be distinguished from patent enforceability. A listed patent can remain relevant to an abbreviated new drug application, but a product withdrawn from the market has little practical value as a reference product unless the sponsor maintains the approval and commercial pathway.
No material U.S. generic market developed around peginesatide after the withdrawal.
Were there Paragraph IV challenges or generic competitors?
No commercially consequential Paragraph IV challenge or generic launch reshaped the U.S. peginesatide market. The short commercial life removed the economic incentive for generic manufacturers to invest in development, patent litigation, manufacturing validation, and regulatory filing.
A generic entrant would have faced several barriers:
- Limited remaining market demand after withdrawal.
- Safety concerns involving severe hypersensitivity.
- The need to establish pharmaceutical equivalence to a complex PEGylated peptide.
- Potential patent disputes involving peptide sequence, conjugation, formulation, and manufacturing.
- The absence of a stable reference-product commercial market.
The more realistic competitive threat came from existing ESAs, not from generic peginesatide. Dialysis providers could shift patients to epoetin, darbepoetin alfa, or other established agents without waiting for a substitute peginesatide product.
What patent litigation and settlement agreements affected Omontys?
The principal commercial legal relationship was the Affymax-Takeda collaboration. The agreement gave Takeda commercialization rights and provided Affymax with milestone payments, royalties, and other economic participation tied to development and sales. Affymax’s SEC filings described the collaboration as central to its business model. [3]
The public record does not show a major generic Paragraph IV litigation campaign or a market-shaping settlement involving peginesatide. The key legal and economic event was the termination of commercial momentum after the recall, followed by the collapse of Affymax’s operating business.
The withdrawal also reduced the value of any patent litigation strategy. Patent enforcement is economically rational only when protected sales justify the cost. Once sales stopped, infringement risk and settlement leverage declined sharply.
How did peginesatide compare with competing ESAs?
| Factor |
Peginesatide |
Epoetin alfa |
Darbepoetin alfa |
Methoxy polyethylene glycol-epoetin beta |
| Dosing differentiation |
Once monthly |
Often more frequent |
Less frequent than epoetin |
Long-acting |
| Product history |
Short U.S. launch |
Extensive |
Extensive |
Established in selected markets |
| Clinical familiarity |
Limited |
High |
High |
Moderate to high |
| Safety concern |
Severe hypersensitivity led to withdrawal |
Class-wide ESA risks |
Class-wide ESA risks |
Class-wide ESA risks |
| Market status |
Withdrawn |
Commercially established |
Commercially established |
Commercially established in relevant markets |
| Generic or biosimilar pressure |
No meaningful U.S. market |
Significant |
Increasing |
Jurisdiction-dependent |
Omontys’ monthly dosing was not unique enough to offset the trust and contracting advantages held by established ESAs. The product also lacked the time required to build comparative evidence, formulary access, and dialysis-provider loyalty.
What generic launch risks existed for peginesatide?
Before withdrawal, a future generic or follow-on product would have faced moderate-to-high technical and regulatory risk. Peginesatide was not a simple small-molecule tablet. It was a complex peptide-PEG conjugate administered by injection, creating potential issues involving molecular characterization, impurity profiles, conjugation heterogeneity, immunogenicity, and clinical comparability.
After withdrawal, commercial risk became dominant. A follow-on manufacturer would have needed to persuade providers to use a molecule associated with fatal hypersensitivity reports. That would have required a compelling safety rationale and probably substantial clinical investment.
The product therefore had a paradoxical profile: significant manufacturing and patent barriers, but weak commercial value after the safety event.
How strong was the peginesatide patent estate?
The patent estate was technically meaningful but commercially impaired.
Factors supporting patent strength
- Composition-of-matter coverage for synthetic erythropoietin-receptor agonist peptides.
- PEGylated drug-substance protection.
- Pharmaceutical composition and injection-related claims.
- Manufacturing and purification know-how.
- Licensing rights held by a major pharmaceutical company.
Factors reducing practical value
- Short commercial exposure.
- No sustained product revenue after 2013.
- No established generic market.
- Severe safety concerns.
- Affymax’s financial collapse.
- Reduced incentive to enforce patents against potential entrants.
Patent strength should therefore be separated into legal scope and asset value. The underlying claims may have been meaningful, but the economic value of those claims fell sharply after the withdrawal.
What was the global and geographic market impact?
The principal impact occurred in the United States, where Omontys had received regulatory approval and entered the dialysis market. The U.S. recall removed the product from the largest commercial opportunity targeted by Affymax and Takeda.
The withdrawal also constrained international expansion. A product without a viable U.S. market faced a weaker basis for additional regulatory filings, manufacturing investment, physician education, and distributor agreements. No durable global commercial franchise emerged.
Geographic barriers included:
- Country-specific approval requirements.
- Different reimbursement systems for dialysis.
- Local pharmacovigilance obligations.
- Manufacturing and cold-chain requirements for injectable biologics or complex peptides.
- Physician reluctance to adopt a withdrawn U.S. product.
What is the long-term commercial outlook for peginesatide acetate?
Peginesatide has no active commercial trajectory comparable to an ongoing branded pharmaceutical. Its value is primarily historical, technical, and intellectual-property related.
A future development program would face a high threshold. It would need to demonstrate that the hypersensitivity risk was linked to a correctable product, process, impurity, or formulation factor. It would also need to compete against established and long-acting ESA products in a market shaped by reimbursement controls and safety restrictions.
The most likely commercial outcome remains no relaunch and no meaningful generic market. The product’s financial trajectory moved from launch-stage revenue to complete commercial discontinuation within approximately 11 months.
Key Takeaways
- Peginesatide acetate was approved as Omontys in March 2012 for CKD-related anemia.
- Its main differentiation was once-monthly dosing.
- Affymax reported about $6.8 million in Omontys net product sales in 2012.
- The product was withdrawn in February 2013 after 25 serious hypersensitivity cases, including seven deaths, among about 12,000 exposed patients.
- Takeda’s commercialization relationship could not produce a durable revenue stream.
- Affymax lost its principal commercial asset and entered a wind-down and bankruptcy-related process.
- No significant U.S. generic launch or Paragraph IV litigation market developed.
- The patent estate had technical relevance, but its economic value collapsed with the product withdrawal.
- Established ESAs retained the market because they combined clinical familiarity, reimbursement infrastructure, and longer commercial histories.
- Peginesatide’s remaining value is primarily archival, technical, or patent-related rather than commercial.
FAQs About Peginesatide Acetate
Is peginesatide acetate still available?
No. Omontys was voluntarily withdrawn from the U.S. market in February 2013 after reports of serious hypersensitivity reactions and deaths.
Who developed Omontys?
Affymax developed peginesatide, and Takeda Pharmaceuticals commercialized the product in the United States under a collaboration agreement.
What caused the Omontys recall?
The recall followed reports of serious hypersensitivity reactions, including anaphylaxis. The FDA reported 25 cases and seven deaths among approximately 12,000 exposed patients.
Did peginesatide have biosimilar competition?
No commercially meaningful biosimilar or generic competition developed after the withdrawal. The product’s short market life and safety history eliminated most follow-on economic incentives.
Could peginesatide be relaunched?
A relaunch would require extensive regulatory, clinical, manufacturing, and safety work. No commercial relaunch occurred, and the product has no established current market presence.
References
-
U.S. Food and Drug Administration. (2012). Omontys (peginesatide) injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2013, February 23). FDA advises dialysis patients and health care professionals about the voluntary recall of Omontys. FDA Drug Safety Communication.
-
Affymax, Inc. (2012). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2012. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA, commonly known as the Orange Book.
